A Phase 3 interventional study of Ixekizumab Auto-Injector and Ixekizumab Prefilled Syringe in Plaque Psoriasis, sponsored by Eli Lilly and Company. Completed at 25 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-30.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.
Among the 22 studies testing ixekizumab in Psoriasis, this one is the 9th largest by enrollment, is the only one that started in 2013, is one of 11 in phase 3, and was the 6th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
Singapore General Hospital · Sites in Singapore
Ages 22–90
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ages 70+
By country, each count listing its studies:
ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 204 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 156 across the 22 interventional studies. Of the 17 that completed or were terminated, 16 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
36 studies in Psoriasis by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 35 finished, 28 (80%) have results posted.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 16th largest by enrollment, is one of 3 that started in 2013, is one of 15 in phase 3, and was the 8th registered.
Eli Lilly and Company’s Psoriasis studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing ixekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 36 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis. Treatment period is followed by 40 weeks optional safety extension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ixekizumab administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection every 2 weeks (Q2W) at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection every 4 weeks (Q4W).
Drug: Ixekizumab Auto-Injector
Ixekizumab administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection Q2W at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection Q4W.
Drug: Ixekizumab Prefilled Syringe
Administered SC by auto-injector
Also known as: LY2439821
Administered SC by prefilled syringe
Also known as: LY2439821
Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) by Drug Delivery Device
Cmax by drug delivery device (prefilled syringe or auto-injector) of Ixekizumab, after the 160 mg starting dose was administered on Day 0.
Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)
PK: Area Under the Concentration Time Curve From Time Zero to Last Measured Concentration Value (AUC 0-[Tlast]) by Drug Delivery Device
AUC 0-tlast by drug delivery device (prefilled syringe or auto-injector) of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours.
Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)
PK: Cmax of Ixekizumab by Site of Injection (Arm, Thigh or Abdomen)
Cmax by site of injection of Ixekizumab, after the 160 mg starting dose was administered on Day 0.
Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)
PK: AUC 0-tlast by Site of Injection (Arm, Thigh or Abdomen)
AUC 0-tlast by site of injection of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours.
Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)
PK: Cmax by Body Weight
Cmax by body weight of Ixekizumab, after the 160 mg starting dose was administered on Day 0. Body weight is defined by (Low: \<80 kilogram (kg), Medium: 80-100 kg, or High: \>100 kg).
Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)
PK: AUC 0-tlast by Body Weight
AUC 0-tlast by body weight of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours. Body weight is defined by (Low: \<80 kg, Medium: 80-100 kg, or High: \>100 kg).
Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)
Percentage of Participants Achieving a ≥75%, ≥ 90% and 100% Improvement in Psoriasis Area and Severity Index (PASI): Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index (PASI)
PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 or no Ps to 72 for the most severe disease. Participants achieving PASI 75, 90, or 100 are defined as having an improvement of at least 75%, 90%, or of 100%, respectively, in the PASI scores compared to baseline.
Time frame: Week 12
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1): Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment (sPGA)
The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.
Time frame: Week 12
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0)
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).
Time frame: Week 12
Percentage of Device Operation Failures
Device operation failure (that is, incomplete dose administration) was defined as an event during the treatment period (week 0 to week 12) when the participant indicated that a complete dose of ixekizumab was not delivered and/or the drug delivery device did not perform as expected per the directions for use.
Time frame: Baseline through Week 12
Percentage of Participants With Anti-Ixekizumab Antibodies
The percentage of participants with treatment-emergent positive anti-ixekizumab antibodies at anytime post-baseline were summarized by drug delivery device group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
Time frame: Baseline to Week 12
SQAAQ Item Scores: Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)
The SQAAQ is a self-administered questionnaire which provides an assessment of ease of use and confidence with using a device to administer a subcutaneous injection of drug. Participants and injection assistants responded to questionnaire items using a 7-point Likert scale (from "Strongly Disagree" to "Strongly Agree"). 1 represents "Strongly Disagree" while 7 represents "Strongly Agree". The ease of use and confidence of ixekizumab subcutaneous administrations across drug delivery device groups were evaluated by SQAAQ item scores at each post baseline visit.
Time frame: Baseline, Week 4 and Week 8
| Milestone | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector |
|---|---|---|
| Started | 102 | 102 |
| Completed | 96 | 94 |
| Not completed | 6 | 8 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Entry criteria not met | 1 | 1 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Milestone | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector |
|---|---|---|
| Started | 94 | 91 |
| Completed | 85 | 78 |
| Not completed | 9 | 13 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 4 |
| Withdrew: Lack of efficacy | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 3 |
Cmax by drug delivery device (prefilled syringe or auto-injector) of Ixekizumab, after the 160 mg starting dose was administered on Day 0.
| micrograms/milliliter (µg/mL) | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector |
|---|---|---|
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) by Drug Delivery Device | 15.0 (13.9 to 16.1) | 14.8 (13.8 to 15.9) |
AUC 0-tlast by drug delivery device (prefilled syringe or auto-injector) of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours.
| micrograms*day/milliliter (µg*day/mL) | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector |
|---|---|---|
| PK: Area Under the Concentration Time Curve From Time Zero to Last Measured Concentration Value (AUC 0-[Tlast]) by Drug Delivery Device | 157 (147 to 168) | 154 (144 to 165) |
Cmax by site of injection of Ixekizumab, after the 160 mg starting dose was administered on Day 0.
| µg/ml | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector |
|---|---|---|
| Arm (n=30, 29) | 14.4 (12.4 to 16.8) | 11.5 (10.1 to 13.0) |
| Abdomen (n=34, 32) | 12.7 (11.3 to 14.2) | 15.4 (13.5 to 17.5) |
| Thigh (n=28, 37) | 18.5 (17.0 to 20.1) | 17.6 (16.0 to 19.4) |
AUC 0-tlast by site of injection of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours.
| µg*day/mL | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector |
|---|---|---|
| Arm (n=30, 29) | 151 (131 to 173) | 124 (109 to 142) |
| Abdomen (n=34, 32) | 135 (122 to 150) | 159 (140 to 180) |
| Thigh (n=28, 37) | 190 (176 to 206) | 178 (163 to 194) |
Cmax by body weight of Ixekizumab, after the 160 mg starting dose was administered on Day 0. Body weight is defined by (Low: \<80 kilogram (kg), Medium: 80-100 kg, or High: \>100 kg).
| µg/mL | 80 mg Ixekizumab |
|---|---|
| Low <80 kg (n=68) | 18.2 (16.9 to 19.5) |
| Medium 80-100 kg (n=64) | 15.1 (13.8 to 16.5) |
| High >100 kg (n=60) | 11.7 (10.8 to 12.7) |
AUC 0-tlast by body weight of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours. Body weight is defined by (Low: \<80 kg, Medium: 80-100 kg, or High: \>100 kg).
| µg*day/mL | 80 mg Ixekizumab |
|---|---|
| Low <80 kilograms (kg) (n=68) | 193 (181 to 205) |
| Medium 80-100 kg (n=64) | 155 (143 to 168) |
| High >100 kg (n=60) | 122 (113 to 132) |
PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 or no Ps to 72 for the most severe disease. Participants achieving PASI 75, 90, or 100 are defined as having an improvement of at least 75%, 90%, or of 100%, respectively, in the PASI scores compared to baseline.
| percentage of participants | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector |
|---|---|---|
| PASI 75 | 88.2 | 78.4 |
| PASI 90 | 76.5 | 62.7 |
| PASI 100 | 48.0 | 42.2 |
The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.
| percentage of participants | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector |
|---|---|---|
| Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1): Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment (sPGA) | 80.4 | 73.5 |
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).
| percentage of participants | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector |
|---|---|---|
| Percentage of Participants With a Static Physician Global Assessment (sPGA) (0) | 51.0 | 43.1 |
Device operation failure (that is, incomplete dose administration) was defined as an event during the treatment period (week 0 to week 12) when the participant indicated that a complete dose of ixekizumab was not delivered and/or the drug delivery device did not perform as expected per the directions for use.
| percentage of incomplete injections | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector |
|---|---|---|
| Percentage of Device Operation Failures | 0 | 0.3 |
The percentage of participants with treatment-emergent positive anti-ixekizumab antibodies at anytime post-baseline were summarized by drug delivery device group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
| percentage of participants | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector |
|---|---|---|
| Percentage of Participants With Anti-Ixekizumab Antibodies | 11.8 | 8.1 |
The SQAAQ is a self-administered questionnaire which provides an assessment of ease of use and confidence with using a device to administer a subcutaneous injection of drug. Participants and injection assistants responded to questionnaire items using a 7-point Likert scale (from "Strongly Disagree" to "Strongly Agree"). 1 represents "Strongly Disagree" while 7 represents "Strongly Agree". The ease of use and confidence of ixekizumab subcutaneous administrations across drug delivery device groups were evaluated by SQAAQ item scores at each post baseline visit.
| units on a scale | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector |
|---|---|---|
| Easy for me to learn how to use, Week 4 (n=94, 90) | 6.6 ± 0.67 | 6.7 ± 0.86 |
| Easy for me to unlock, Week 4 (n=86, 90) | 6.6 ± 0.81 | 6.8 ± 0.74 |
| Easy to hold in hand, Week 4 (n=94, 90) | 6.6 ± 0.70 | 6.6 ± 0.91 |
| Easy to inject my dose, Week 4 (n=94, 90) | 6.6 ± 0.76 | 6.7 ± 0.83 |
| Easy to know dose is complete, Week 4 (n=94, 90) | 6.7 ± 0.53 | 6.7 ± 0.79 |
| Easy to store in refrigerator, Week 4 (n=91, 88) | 6.7 ± 0.54 | 6.7 ± 0.77 |
| Easy to remove needle shield, Week 4 (n=94, 90) | 6.6 ± 0.79 | 6.6 ± 0.95 |
| Easy to pick up, Week 4 (n=94, 90) | 6.8 ± 0.56 | 6.7 ± 0.80 |
| Overall, easy to use, Week 4 (n=94, 90) | 6.6 ± 0.70 | 6.7 ± 0.82 |
| Device is stable against skin, Week 4 (n=93, 90) | 6.6 ± 0.81 | 6.6 ± 1.05 |
| Confident in ability to use, Week 4 (n=94, 90) | 6.7 ± 0.62 | 6.7 ± 0.83 |
| Confident my dose is complete, Week 4 (n=94, 90) | 6.8 ± 0.44 | 6.8 ± 0.71 |
| Easy for me to learn how to use, Week 8 (n=89, 92) | 6.7 ± 0.63 | 6.8 ± 0.69 |
| Easy for me to unlock, Week 8 (n=87, 92) | 6.6 ± 0.67 | 6.8 ± 0.69 |
| Easy to hold when I inject dose, Week 8 (n=89, 92) | 6.6 ± 0.67 | 6.7 ± 0.94 |
| Easy to inject my dose, Week 8 (n=89, 92) | 6.5 ± 0.80 | 6.8 ± 0.82 |
| Easy to know dose is complete, Week 8 (n=89, 92) | 6.7 ± 0.52 | 6.8 ± 0.70 |
| Easy to store in refrigerator, Week 8 (n=89, 92) | 6.7 ± 0.62 | 6.8 ± 0.72 |
| Easy to remove needle shield, Week 8 (n=89, 92) | 6.6 ± 0.75 | 6.7 ± 0.89 |
| Easy to pick up, Week 8 (n=89, 92) | 6.7 ± 0.63 | 6.8 ± 0.68 |
| Overall, easy to use, Week 8 (n=89, 92) | 6.6 ± 0.76 | 6.8 ± 0.74 |
| Device is stable against skin, Week 8 (n=88, 92) | 6.6 ± 0.81 | 6.6 ± 1.10 |
| Confident in ability to use, Week 8 (n=89, 92) | 6.7 ± 0.77 | 6.8 ± 0.71 |
| Confident my dose is complete, Week 8 (n=89, 92) | 6.7 ± 0.47 | 6.8 ± 0.70 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 80 mg Ixekizumab Prefilled Syringe Treatment Period | — | 3/102 (2.9%) | 12/102 (11.8%) |
| 80 mg Ixekizumab Auto-Injector Treatment Period | — | 4/102 (3.9%) | 10/102 (9.8%) |
| 80 mg Ixe Prefilled Syringe Optional Safety Extension | — | 9/185 (4.9%) | 24/185 (13%) |
| Follow Up Period | — | 1/176 (0.6%) | 0/176 (0%) |
| Event | 80 mg Ixekizumab Prefilled Syringe Treatment Period | 80 mg Ixekizumab Auto-Injector Treatment Period | 80 mg Ixe Prefilled Syringe Optional Safety Extension | Follow Up Period |
|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/102 | 0/102 | 2/185 | 0/176 |
| Acute myocardial infarctionCardiac disorders | 0/102 | 1/102 | 0/185 | 0/176 |
| Anaphylactic reactionImmune system disorders | 0/102 | 1/102 | 0/185 | 0/176 |
| DiverticulitisInfections and infestations | 1/102 | 0/102 | 1/185 | 0/176 |
| Tooth abscessInfections and infestations | 0/102 | 1/102 | 0/185 | 0/176 |
| Urinary tract infectionInfections and infestations | 1/102 | 0/102 | 0/185 | 0/176 |
| Hip fractureInjury, poisoning and procedural complications | 0/102 | 1/102 | 0/185 | 0/176 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/102 | 0/102 | 0/185 | 0/176 |
| CellulitisInfections and infestations | 0/102 | 0/102 | 1/185 | 1/176 |
| Cardio-respiratory arrestCardiac disorders | 0/102 | 0/102 | 1/185 | 0/176 |
| Event | 80 mg Ixekizumab Prefilled Syringe Treatment Period | 80 mg Ixekizumab Auto-Injector Treatment Period | 80 mg Ixe Prefilled Syringe Optional Safety Extension | Follow Up Period |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 4/102 | 5/102 | 16/185 | 0/176 |
| Injection site reactionGeneral disorders | 8/102 | 5/102 | 8/185 | 0/176 |
| Age, Continuous(years) | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector | Total |
|---|---|---|---|
| Mean | 46.3 ± 14.53 | 46.8 ± 13.09 | 46.5 ± 13.80 |
| Sex: Female, Male(Participants) | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector | Total |
|---|---|---|---|
| Female | 31 | 31 | 62 |
| Male | 71 | 71 | 142 |
| Ethnicity (NIH/OMB)(Participants) | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector | Total |
|---|---|---|---|
| Hispanic or Latino | 33 | 29 | 62 |
| Not Hispanic or Latino | 69 | 73 | 142 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 4 | 2 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 13 | 5 | 18 |
| White | 82 | 95 | 177 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector | Total |
|---|---|---|---|
| Puerto Rico | 19 | 20 | 39 |
| United States | 83 | 82 | 165 |
| Baseline in Psoriasis Area and Severity Index (PASI)(units on a scale) | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector | Total |
|---|---|---|---|
| Mean | 21.05 ± 9.379 | 17.76 ± 6.141 | 19.40 ± 8.078 |
| Baseline in Static Physician Global Assessment (sPGA) Score(participants) | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector | Total |
|---|---|---|---|
| sPGA=3 | 55 | 53 | 108 |
| sPGA=4, 5 | 47 | 49 | 96 |
| Baseline in Subcutaneous Administration Assessment Questionnaire (SQAAQ)(units on a scale) | 80 mg Ixekizumab Prefilled Syringe | 80 mg Ixekizumab Auto-Injector | Total |
|---|---|---|---|
| Easy for me to learn how to use (n=99,101) | 6.4 ± 1.08 | 6.7 ± 0.91 | 6.6 ± 1.01 |
| Easy for me to unlock (n=93,101) | 6.4 ± 0.94 | 6.7 ± 1.01 | 6.6 ± 0.98 |
| Easy to hold in hand when I inject dose (n=99,101) | 6.3 ± 1.27 | 6.6 ± 0.97 | 6.4 ± 1.14 |
| Easy to inject my dose (n=99,101) | 6.2 ± 1.32 | 6.6 ± 1.00 | 6.4 ± 1.18 |
| Easy to know that my dose is complete (n=99,101) | 6.4 ± 1.20 | 6.7 ± 0.93 | 6.6 ± 1.07 |
| Easy to store device in refrigerator (n=94, 97) | 6.5 ± 0.88 | 6.6 ± 1.00 | 6.5 ± 0.94 |
| Easy to remove needle shield/cover (n=99, 100) | 6.6 ± 0.67 | 6.6 ± 1.09 | 6.6 ± 0.91 |
| Easy to pick up (n=99, 100) | 6.7 ± 0.67 | 6.7 ± 0.94 | 6.7 ± 0.81 |
| Overall, easy to use (n=99,101) | 6.4 ± 1.10 | 6.6 ± 0.99 | 6.5 ± 1.05 |
| Device is stable during injection (n=99, 101) | 6.3 ± 1.18 | 6.6 ± 1.06 | 6.5 ± 1.12 |
| Confident in ability to use the device (n=99, 101) | 6.4 ± 1.16 | 6.7 ± 1.06 | 6.5 ± 1.12 |
| I am confident my dose is complete (n=98,101) | 6.6 ± 1.09 | 6.7 ± 0.89 | 6.6 ± 0.99 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Mar 2013, a primary completion of May 2014 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 2 years after primary completion. A results delay was requested in Sep 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab